Vanita R. Aroda, M.D., Associate Professor of Medicine and Director, Diabetes Clinical Research at Brigham and Women's Hospital/Harvard Medical School, presented "The Role of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Mitigating Cardiorenal Metabolic Risk" at University of Louisville Department of Medicine Grand Rounds on October 14, 2021.
Dr. Aroda's talk focused on discussing the scope and potential impact of cardiorenal and metabolic risk mitigation in type 2 diabetes, describing evidence on the role of GLP-1 receptor agonists and SGLT2 inhibitors in improving cardiovascular and renal outcomes, and examining updates in guidelines pertaining to use of diabetes therapeutic agents for cardiorenal risk reduction.
Presented by the UofL Division of Endocrinology, Metabolism & Diabetes.
